Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | PTPRF | P10586 | 1/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.47 |
| ▸ | MEN1 | O00255 | 7/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.47 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CTSV | O60911 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7665374 | 0.82 | SMN1; SMN2 (0.61) | SMN1; SMN2KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL17737227 | 0.82 | SMN1; SMN2 (0.53) | SMN1; SMN2KMT2AMEN1MAPTGAA | |
| SCHEMBL7239815 | 0.81 | ALDH1A1 (0.48) | SMN1; SMN2KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL20968366 | 0.79 | SMN1; SMN2 (0.57) | SMN1; SMN2KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL550921 | 0.79 | SMN1; SMN2 (0.57) | SMN1; SMN2KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL20968303 | 0.78 | SMN1; SMN2 (0.56) | SMN1; SMN2KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL10514258 | 0.78 | SMN1; SMN2 (0.56) | SMN1; SMN2KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL6582296 | 0.77 | SMN1; SMN2 (0.65) | SMN1; SMN2KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL7723906 | 0.77 | SMN1; SMN2 (0.68) | SMN1; SMN2KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL7116626 | 0.76 | SMN1; SMN2 (0.64) | SMN1; SMN2KMT2AMEN1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6583144-B2 | Piperazine substituted isoquinoline, 1,3-benzoxazine, or 1,3-benzothiazine derivatives; inhibitors against the biosynthesis of triglycerides and secretion of apolipoprotein b and treatment of hyperlipidemia | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-06-24 | — | — | US | disclosed |
| US-20020156276-A1 | Nitrogen-containing heterocyclic compounds and therapeutic agents for hyperlipidemia comprising the same | OHKURA NAOTO (JP) | 2002-10-24 | — | — | US | disclosed |
| US-6417362-B1 | PIPERAZINE DERIVATIVES; ARTERIOSCLEROSIS, PANCREATITIS, AND CARDIOVASCULAR DISORDER TREATMENT; SIDE EFFECT REDUCTION | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-07-09 | — | — | US | disclosed |
| EP-0999208-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS AND HYPERLIPEMIA REMEDY CONTAINING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2000-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156276-A1 | Nitrogen-containing heterocyclic compounds and therapeutic agents for hyperlipidemia comprising the same | APOB, PNLIP, NR1H2 | SMN1; SMN2 2065/4885MAOB 367/4885PTPRF 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.